Omigapil

Phase 1Small molecule

SSanthera Pharmaceuticals

Omigapil is one of 20 small molecule programs targeting Muscular Dystrophy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Muscular DystrophyActive, not recruiting

Muscular DystrophyPhase 1

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Muscular Dystrophy

#DrugCompanyPhaseTrials

Cialis

Glucophage

Duvyzat

1 4

Glucocorticoid

AbbVie

Phase 3

1 5

Rayos

RRoxane Laboratories

Phase 2

1 6

Emflaza

PPTC Therapeutics

Phase 3

1 7

Translarna

PPTC Therapeutics

Phase 2

—8

Bisphosphonate Treatment

UUniversité Catholique de Louvain

Approved

1 9

Stem Cell

NNeurogen Brain and Spine Institute

Phase 2

3 10

Trehalose

SSeelos Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Muscular Dystrophy1 trial

Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)

Completed·SSanthera Pharmaceuticals·Phase 1·NCT01805024·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Omigapil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Omigapil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Omigapil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Santhera Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSanthera Pharmaceuticals

Omigapil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Muscular Dystrophy1 trial

References

Drug Info

Quick Facts

Related News